Screener
Myriad Genetics MYGN Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Myriad Genetics’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 6:05 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000899923-26-000038
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Other assets | (0.5) | 0.5 |
| Accounts payable | 5.4 | — |
| Accrued liabilities | (7.4) | (12.4) |
| Net cash used in operating activities | (15.7) | (16.3) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Capital expenditures | (5.4) | (5.3) |
| Capitalization of intangible assets | (1.1) | (3.0) |
| Net cash used in investing activities | (6.5) | (8.3) |
Item 1. Financial Statements.
FAQ
- What is Myriad Genetics's operating cash flow?
- Myriad Genetics (MYGN) reported operating cash flow of -$15.7M in Q1 2026.
- How has Myriad Genetics's operating cash flow changed year-over-year?
- Myriad Genetics's operating cash flow increased by 3.7% year-over-year, from -$16.3M to -$15.7M.
- What is the long-term trend for Myriad Genetics's operating cash flow?
- Over 2 years (2022 to 2025), Myriad Genetics's operating cash flow has grown at a -87.0% compound annual growth rate (CAGR), from -$106.3M to $1.8M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Myriad Genetics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude